# **Supplementary Information**

## Contents

Supplementary figures	2
Supplementary data dictionary	3

# **Supplementary figures**



#### Q-Q Plot: GWAS meta-analysis

**Supplementary Fig. 1** | **Quantile-quantile plot Parkinson's disease replication cohort.** Scatter plot of the observed versus expected  $-\log_{10}(p\text{-values})$  generated by the meta-analysis of case-control genome-wide association study data used for the replication step for Parkinson's disease risk.

## Supplementary data dictionary

Below are definitions and descriptions for column headings used in supplementary tables. **beta:** MR effect size.

beta\_lci95: Lower boundary of 95% confidence interval of the MR effect size (beta).

**beta\_uci95:** Upper boundary of 95% confidence interval of the MR effect size (beta).

chr\_name: Chromosome of the gene tested.

clump\_tresh: Clumping threshold used

cochrans\_q: Cochran's Q.

cochrans\_q\_pval: Cochran's Q p-value.

druggability\_tier: Druggability tier for the gene as defined by Finan et al. 2017 (PMID: 28356508).

1 = genes encoding targets of approved and clinical-phase drugs. 2 = genes encoding proteins that are targeted by small, drug-like molecules in vivo, and genes that are highly similar to approved drug targets. 3 and 4 = genes encoding extracellular or secreted proteins, genes with some similarity to approved drug targets, and genes which belong to key druggable gene families, if not already included in tiers 1 and 2. Of these, genes in tier 3 were in within ±50 kilobases of a GWAS SNP and encoded an extracellular protein. The remainder were put in tier 4."

egger\_intercept: MR-Egger intercept.

egger\_intercept\_95\_ci: 95% confidence intervals of the MR-Egger intercept.

egger\_intercept\_pvalue: P-value of the MR-Egger intercept.

**exposure:** Name of the gene tested.

fdr\_qval: False discovery rate-corrected p-value (also called a q-value).

3

gene\_end: Base pair position of gene end.

gene\_start: Base pair position of gene start.

i2: I^2 value

method: Method used to calculate the MR effect estimate.

**nsnp:** Number of SNPs used for the MR calculation.

or: Odds ratio.

or\_lci95: Lower boundary of 95% confidence interval of the MR effect size (odds ratio).

or\_uci95: Upper boundary of 95% confidence interval of the MR effect size (odds ratio).

outcome: Name of the outcome tested.

**p:** Raw p-value.

- **p1:** Colocalization data; prior probability that a SNP in the tested region is significantly associated with expression of the tested gene.
- **p12:** Colocalization data; prior probability that a SNP in the tested region is significantly associated with both expression of the tested gene and the tested PD outcome.
- **p2:** Colocalization data; prior probability that a SNP in the tested region is significantly associated with expression of the tested PD outcome.
- **PP.H0.abf:** Colocalization data; PPH0, posterior probability that there is no association with either trait.
- **PP.H1.abf:** Colocalization data; PPH1, posterior probability that there is association with expression of the gene, but not the PD trait.
- **PP.H2.abf**: Colocalization data; PPH2, posterior probability that there is association with the PD trait, but not expression of the gene.

- **PP.H3.abf:** Colocalization data; PPH3, posterior probability that there is association with the PD trait and expression of the gene, with distinct causal variants.
- **PP.H4.abf:** Colocalization data; PPH4, posterior probability that there is association with the PD trait and expression of the gene, with a shared causal variant.

se: Standard error.

- sum\_pph3\_pph4: Colocalization data; sum of PPH3 and PPH4. PPH3+PPH4 < 0.8 indicated low power for colocalization.
- **tissue\_qtl\_type:** Tissue in which expression of the gene was measured (blood or brain), and the QTL type (expression of protein levels).